Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Statements of Stockholders' Equity

v3.22.2
Unaudited Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Series F Convertible Preferred Stock
Series F Convertible Preferred Stock
Additional Paid-In Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020   8,651,400 21,754    
Beginning balance at Dec. 31, 2020 $ (28,102) $ 9 $ 0 $ 232,530 $ (260,641)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Shares and warrants issued pursuant to private placement (in shares)   546,733      
Shares and warrants issued pursuant to private placement 4,072 $ 1   4,071  
Share-based compensation (in shares)   17,537      
Share-based compensation 2,544     2,544  
Warrant exercises (in shares)   297,383      
Warrant exercises 1,310     1,310  
Shares issued to third-party for services (in shares)   5,000      
Shares issued to third-party for services 46     46  
Warrant modifications 0     402 (402)
Conversion of Series F shares to common stock (in shares)   1,482,672 (4,448)    
Conversion of Series F shares to common stock 0 $ 1   (1)  
Net (loss) income available to common stockholders (12,850)       (12,850)
Ending balance (in shares) at Mar. 31, 2021   11,000,725 17,306    
Ending balance at Mar. 31, 2021 (32,980) $ 11 $ 0 240,902 (273,893)
Beginning balance (in shares) at Dec. 31, 2020   8,651,400 21,754    
Beginning balance at Dec. 31, 2020 (28,102) $ 9 $ 0 232,530 (260,641)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net (loss) income available to common stockholders 11,926        
Ending balance (in shares) at Jun. 30, 2021   15,821,559 17,294    
Ending balance at Jun. 30, 2021 14,260 $ 16 $ 0 263,361 (249,117)
Beginning balance (in shares) at Mar. 31, 2021   11,000,725 17,306    
Beginning balance at Mar. 31, 2021 (32,980) $ 11 $ 0 240,902 (273,893)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Share-based compensation 313     313  
Warrant exercises (in shares)   83,333      
Warrant exercises 375     375  
Conversion of Series F shares to common stock (in shares)   4,000 (12)    
Conversion of convertible notes to common stock (in shares)   4,732,420      
Conversion of convertible notes to common stock 21,776 $ 5   21,771  
Shares issued in lieu of fractional shares due to reverse stock split (in shares)   1,081      
Net (loss) income available to common stockholders 24,776       24,776
Ending balance (in shares) at Jun. 30, 2021   15,821,559 17,294    
Ending balance at Jun. 30, 2021 14,260 $ 16 $ 0 263,361 (249,117)
Beginning balance (in shares) at Dec. 31, 2021   29,146,367      
Beginning balance at Dec. 31, 2021 57,875 $ 29   317,102 (259,256)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Share-based compensation (in shares)   218,345      
Share-based compensation 1,091     1,091  
Net (loss) income available to common stockholders (4,040)       (4,040)
Ending balance (in shares) at Mar. 31, 2022   29,364,712      
Ending balance at Mar. 31, 2022 54,926 $ 29   318,193 (263,296)
Beginning balance (in shares) at Dec. 31, 2021   29,146,367      
Beginning balance at Dec. 31, 2021 57,875 $ 29   317,102 (259,256)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net (loss) income available to common stockholders (8,407)        
Ending balance (in shares) at Jun. 30, 2022   29,364,712      
Ending balance at Jun. 30, 2022 51,360 $ 29   318,994 (267,663)
Beginning balance (in shares) at Mar. 31, 2022   29,364,712      
Beginning balance at Mar. 31, 2022 54,926 $ 29   318,193 (263,296)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Share-based compensation 801     801  
Net (loss) income available to common stockholders (4,367)       (4,367)
Ending balance (in shares) at Jun. 30, 2022   29,364,712      
Ending balance at Jun. 30, 2022 $ 51,360 $ 29   $ 318,994 $ (267,663)